Mustafa Demirbker - XSpray Pharma CoFounder Director
| XSPRAY Stock | SEK 42.10 0.10 0.24% |
Insider
Mustafa Demirbker is CoFounder Director of XSpray Pharma AB
| Phone | 46 87 30 37 00 |
| Web | https://www.xspraypharma.com |
XSpray Pharma Management Efficiency
The company has return on total asset (ROA) of (0.1448) % which means that it has lost $0.1448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2423) %, meaning that it generated substantial loss on money invested by shareholders. XSpray Pharma's management efficiency ratios could be used to measure how well XSpray Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Rohit Batta | Vicore Pharma Holding | N/A | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Nina Ivers | Xbrane Biopharma AB | 53 | |
| Thoas MD | Cantargia AB | 61 | |
| CarlJohan MD | Vicore Pharma Holding | 67 | |
| Marcuss | Cantargia AB | N/A | |
| Kicki Johansson | Vicore Pharma Holding | 65 | |
| Harald Borgeke | BioArctic AB | N/A | |
| Jessica Shull | Vicore Pharma Holding | N/A | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| David Vikstrm | Xbrane Biopharma AB | 46 | |
| Christer Mller | BioArctic AB | 64 | |
| Dominique Tersago | Cantargia AB | 61 | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Associate Gier | Xbrane Biopharma AB | N/A | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Adnan Deronic | Cantargia AB | N/A | |
| Hans Jeppsson | Vicore Pharma Holding | N/A | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 |
XSpray Pharma AB Leadership Team
Elected by the shareholders, the XSpray Pharma's board of directors comprises two types of representatives: XSpray Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XSpray. The board's role is to monitor XSpray Pharma's management team and ensure that shareholders' interests are well served. XSpray Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XSpray Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kerstin Hasselgren, Chief Officer | ||
| Per Andersson, Chief Officer | ||
| Charlotta Liljebris, VP RD | ||
| Andreas Konar, Sr Devel | ||
| Thomas Walz, Chief Officer | ||
| AnnaKarin Ekberg, VP Sales | ||
| Christina Hagerstrand, VP Relations | ||
| Grald Jesson, VP Operations | ||
| Mustafa Demirbker, CoFounder Director |
XSpray Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XSpray Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (116.51) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 22.68 M | |||
| Shares Owned By Insiders | 47.42 % | |||
| Shares Owned By Institutions | 27.60 % | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 1,206 X | |||
| Gross Profit | 656 K |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.